Hello Heart has raised $70 million in fourth-round financing to help grow its smartphone-based technology for people seeking to improve their heart health.
Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for
Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.
Bayer's two-year-old digital health collaboration with One Drop has borne its first fruit, an artificial intelligence-powered software module for preventing cardiovascular disease (CVD).
Novartis has joined forces with a group representing cardiovascular disease patients organisations to push for changes in how health systems handle the world's number one killer.